The orthopedic market is on the cusp of transformation.

 Orthoworld’s recent article, “Opportunities in Knee OA Hold Tremendous Promise” (Aug 1, 2025), highlights more than 90 new therapies in development — from injectables to biologics — with some nearing FDA approval as early as 2026.

ORTHOWORLD.

The future of knee OA is clearly shifting toward less invasive, patient-centered care. OrthoLazer is already part of that future. 

• Earlier intervention: Laser can be introduced well before surgical consideration, helping patients manage pain and function while potentially delaying more invasive procedures.
• Adjunctive therapy: PBMT fits seamlessly with rehab therapies, NSAIDs, and injectables, creating a stronger multimodal approach.
• Immediate access: Unlike pipeline therapies, OL is here now — delivering non-invasive pain relief and driving faster injury and surgical recovery.
• Aligned with market demand — Patients and providers are calling for cost-effective, low-risk options — OL delivers on that need now.

The article makes clear: the future of knee OA treatment is moving toward less invasive, more accessible, and patient-centered solutions. OrthoLazer Centers are leading this revolution, everyday, in every community we serve.

Thank you for your continued and passionate support of laser therapy for your patients.

Want more Clinical News? All previous editions are archived here!